Patent · US Active

Methods for treating suicidal ideation

US9539220B2 · kind B2 · utility

4Cited by
3References
9Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 5, 2014
Grant dateJan 10, 2017
Priority date
Expiry dateMar 5, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.